LDL

Heart

Icosapent Ethyl to Reduce Atherosclerotic Events in Patients with Hypertriglyceridemia

By Omid Kiamanesh, MD, FRCPC on August 26, 2020

Despite intensive lowering of LDL-C using lipid-modifying therapy, residual ASCVD risk persists, particularly in those with hypertriglyceridemia. Icosapent ethyl has been shown to reduce residual ASCVD risk and cardiovascular death in select patients with hypertriglyceridemia while on statin therapy.

Heart

Elevated Lipoprotein (a) is a common reason for unexplained premature or recurrent coronary heart disease and stroke

By Dr. Gordon Francis on April 26, 2017

High Lp(a) is a major CVD risk factor that should be measured and acted upon in patients and families where there is history of premature CV events but lack of clear risk factors, and in patients with known CVD and recurrent events despite treatment to LDL-C target.

What's new in dyslipidemia by Dr. Jiri Frohlich

What’s new in dyslipidemia

By Dr. Jiri Frohlich on August 20, 2012

Several studies established that apo B is a better predictor of risk both at baseline and on treatment than LDL-C due to the fact that small dense LDL particles are much more atherogenic as they easily penetrate the endothelial space.

Visit UBC CPD at ubccpd.ca

UBC CPD website

View all CPD learning activities: virtual, in-person and hybrid conferences, workshops, webinars, online modules, customized community courses, simulation hands-on courses, coaching, mentoring, personalized learning, recordings, and more.

Visit UBC CPD ↗

This field is for validation purposes and should be left unchanged.